Spots Global Cancer Trial Database for stage iv uveal melanoma ajcc v7

Every month we try and update this database with for stage iv uveal melanoma ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	NCT01979523	Recurrent Uveal... Stage IV Uveal ...	Laboratory Biom... Pharmacological... Trametinib Uprosertib	18 Years -	National Cancer Institute (NCI)
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma	NCT02363283	Recurrent Uveal... Stage IV Uveal ...	Glembatumumab V... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery	NCT02158520	Metastatic Mela... Mucosal Melanom... Stage IV Cutane... Stage IV Uveal ... Unresectable Me...	Bevacizumab Ipilimumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Academic and Community Cancer Research United
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery	NCT01835145	Recurrent Uveal... Stage III Uveal... Stage IIIA Uvea... Stage IIIB Uvea... Stage IIIC Uvea... Stage IV Uveal ...	Cabozantinib S-... Dacarbazine Laboratory Biom... Temozolomide	18 Years -	National Cancer Institute (NCI)
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma	NCT02363283	Recurrent Uveal... Stage IV Uveal ...	Glembatumumab V... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma	NCT01585194	Metastatic Uvea... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab	18 Years -	M.D. Anderson Cancer Center
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma	NCT01585194	Metastatic Uvea... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab	18 Years -	M.D. Anderson Cancer Center
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	NCT01979523	Recurrent Uveal... Stage IV Uveal ...	Laboratory Biom... Pharmacological... Trametinib Uprosertib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: